ATPW
VYNE icon

Ashton Thomas Private Wealth’s VYNE Therapeutics VYNE Stock Holding History

Ashton Thomas Private Wealth’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19
Closed -$37 – 1829
2024
Q2 		$37 Buy
+19
New +$47 ﹤0.01% 1923

Other funds holding VYNE

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $100M AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Ashton Thomas Private Wealth's VYNE Position: Q3 2024 in Review

Ashton Thomas Private Wealth sold out of VYNE Therapeutics (VYNE) in Q3 2024, closing a stake of 19 shares — an estimated $37 sold.

Ashton Thomas Private Wealth first reported a position in VYNE in Q2 2024 and held it in 1 quarter. The position peaked at $37 in Q2 2024. 33 funds tracked by Wall St. Rank hold VYNE as of Q3 2024.

  • Ashton Thomas Private Wealth reported no remaining VYNE Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Ashton Thomas Private Wealth sold 19 VYNE Therapeutics shares in Q3 2024, an estimated $37.
  • Ashton Thomas Private Wealth first reported a position in VYNE Therapeutics in Q2 2024 and held it in 1 quarter.
  • Ashton Thomas Private Wealth's VYNE Therapeutics position peaked at $37 in Q2 2024.
  • 33 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2024.

Based on Ashton Thomas Private Wealth's 13F filing for Q3 2024, filed 5 Nov 2024.